No Detail Found!

Comparative study of Sitagliptin versus Metformin as an initial monotherapy in newly diagnosed Type 2 Diabetic subjects

Author(s)
Azhar Memon Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Kashif Rasheed Shaikh Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Muhammad Atif Ata Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Umair Ali Soomro Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Shumaila Shaikh Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Shumail Saeed Siddiqui Department of Pharmacology, Suleman Roshan Medical College, Indus Medical College, Tando Muhammad Khan, Sindh, Pakistan
Abstract
Objective: To analyze and compare the pharmacological efficacy of sitagliptin and metformin in terms of blood glucose and glycated HbA1 in type 2 diabetes mellitus (T2DM) patients. Methodology: This observational study was conducted at the Suleman Roshan Medical College from March 2019 to February 2020. A sample of 200 diagnosed cases of type 2 DM, were assigned as 100 to sitagliptin and 100 to metformin. Sample was selected by non-probability convenient sampling. After 12 week's therapy, the blood samples were taken for biochemical analysis. Fasting (FBG), random blood glucose (RBG) and glycated HbA1 (HbA1c) were estimated by standard methods. Data were analyzed on SPSS version 21.0. Results: Age of Sitagliptin group was 49.6 ± 5.7 and Metformin group was 49.7 ± 6.5 years (p = 0.07). FBG in sitagliptin decreased by 46% vs. 37% in metformin; RBG in sitagliptin decreased by 90% vs. 69% in metformin and HbA1c decreased by 14.35 in sitagliptin vs. 11.4% in metformin. Nausea, vomiting, diarrhea and headache were noted in 3%, 3%, 6% and 5% of those taking sitagliptin compared to 19%, 5%, 13% and 11% in metformin treated patients, respectively (p < 0.05). Conclusion: Sitagliptin monotherapy achieved effective glycemic control with fewer complications compared to metformin. Sitagliptin showed fewer chances of nausea, vomiting, diarrhea and headache.
Publication Details
Page(s) 532-535
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 47, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Type 2 diabetes mellitus, sitagliptin, Glycemic control, metformin
0

Citations

0

Downloads

69

Views